Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2015

Summary of Significant Accounting Policies

Analysis of U.S. product sales allowances and accruals

	Three Months Ended March 31,
	2015		2014
Gross U.S. product sales	$	125,517	$	31,661
Provision for U.S. product sales allowances and accruals:
Contractual adjustments	35,134		13,973
Governmental rebates	12,968		165
Total provision for U.S product sales allowances and accruals	48,102		14,138
U.S. product sales, net	$	77,415	$	17,523

Schedule of customers representing 10% or more of revenues

	Three Months Ended March 31,
	2015	2014
AmerisourceBergen Drug Corporation	30%	39%
Takeda Pharmaceuticals Company Limited	13%	11%
McKesson Corporation	10%	22%
Cardinal Health, Inc.	<10%	15%